drugset / Trial / NCT05160285
Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to explore efficacy and safety of neoadjuvant nivolumab for non-metastatic upper tract urothelial carcinoma (UTUC), and explore the potential predictive biomarkers of immunotherapy.
Timeline
- Start
- 2020-12-25
- Primary completion
- 2023-12-15
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 360 mg | Intravenous |